The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Dawn Svoronos Biography and Net Worth

Director of PTC Therapeutics

Dawn Svoronos has served as a member of PTC’s board of directors since June 2016. She has over 30 years of experience in the pharmaceutical industry, including extensive commercial work at Merck & Co. Inc., where she held roles of increasing seniority for 23 years, prior to her retirement in 2011 as President of Merck’s Europe/Canada region. Previously, Ms. Svoronos served at Merck as President of Canada, Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos is currently chair of the board of directors for Theratechnolgies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange as well as the Nasdaq exchange. Ms. Svoronos also serves on the boards of Xenon Pharmaceuticals Inc. and Global Blood Therapeutics, both Nasdaq-listed biopharmaceutical companies and is also a member of the board of Agnovos Healthcare Company, a privately held organization in New York. Ms. Svoronos received a BA from Carleton University.

What is Dawn Svoronos' net worth?: The estimated net worth of Dawn Svoronos is at least $696,500.00 as of August 24th, 2023. Ms. Svoronos owns 25,000 shares of PTC Therapeutics stock worth more than $696,500 as of April 26th. This net worth estimate does not reflect any other investments that Ms. Svoronos may own. Learn More about Dawn Svoronos' net worth.
How do I contact Dawn Svoronos?: The corporate mailing address for Ms. Svoronos and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Dawn Svoronos' contact information.
Has Dawn Svoronos been buying or selling shares of PTC Therapeutics?: Dawn Svoronos has not been actively trading shares of PTC Therapeutics during the past quarter. Most recently, Dawn Svoronos sold 365 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $41.88, for a transaction totalling $15,286.20. Following the completion of the sale, the director now directly owns 27,065 shares of the company's stock, valued at $1,133,482.20. Learn More on Dawn Svoronos' trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Dawn Svoronos (Director), and Christine Utter (CAO). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 69,128 shares worth more than $2,672,029.04. The most recent insider tranaction occured on April, 19th when CEO Matthew B Klein sold 3,361 shares worth more than $83,655.29. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 4/19/2024.

Dawn Svoronos Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	365	$41.88	$15,286.20	27,065
2/1/2021	Sell	506	$56.96	$28,821.76	27,430
5/23/2017	Buy	25,000	$13.49	$337,250.00	25,000

Dawn Svoronos Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $28.57

$25.67

$29.27

50 Day Range

MA: $28.15

$24.69

$31.95

2 Week Range

Now: $28.57

$17.53

$59.84

Volume

1,520,930 shs

Average Volume

970,034 shs

Market Capitalization

$2.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67